Stockscreener 앱 받기
2.40
1.44%
-0.035
전일 마감가:
$2.435
열려 있는:
$2.43
하루 거래량:
47,816
Relative Volume:
0.03
시가총액:
$75.73M
수익:
-
순이익/손실:
$-69.00M
주가수익비율:
-0.8633
EPS:
-2.78
순현금흐름:
$-55.26M
1주 성능:
+1.69%
1개월 성능:
+18.23%
6개월 성능:
+92.00%
1년 성능:
-62.73%
1일 변동 폭
$2.40
$2.445
1주일 범위
$2.16
$2.55
52주 변동 폭
$1.05
$8.00
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
명칭
Acrivon Therapeutics Inc
전화
617-207-8979
주소
480 ARSENAL WAY, SUITE 100, WATERTOWN
ACRV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
2.40 | 76.05M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.80 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
912.98 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.74 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-05 | 재개 | Piper Sandler | Overweight |
| 2025-01-31 | 개시 | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | 개시 | JMP Securities | Mkt Outperform |
| 2023-12-15 | 재개 | Jefferies | Buy |
| 2023-10-05 | 개시 | Maxim Group | Buy |
| 2023-06-02 | 개시 | Oppenheimer | Outperform |
| 2023-05-08 | 개시 | BMO Capital Markets | Outperform |
| 2023-04-27 | 개시 | Ladenburg Thalmann | Buy |
| 2023-04-20 | 개시 | H.C. Wainwright | Buy |
| 2022-12-12 | 개시 | Cowen | Outperform |
| 2022-12-12 | 개시 | Jefferies | Buy |
| 2022-12-12 | 개시 | Piper Sandler | Overweight |
모두보기
Acrivon Therapeutics Inc 주식(ACRV)의 최신 뉴스
How Acrivon Therapeutics Inc. stock reacts to bond yieldsBond Market & AI Forecasted Entry and Exit Points - Newser
Get in on Acrivon Therapeutics Inc’s (ACRV) buy-in window today! - Setenews
H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With “Buy” Rating and $19 PT - Insider Monkey
Investors in cash trouble should check out Acrivon Therapeutics Inc (ACRV) - Setenews
Acrivon Therapeutics Enhances Tumor-Specific Treatment Models - Kalkine Media
HC Wainwright Reiterates Buy Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics' (ACRV) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Citadel Advisors LLC Acquires Additional Shares in Acrivon Therapeutics Inc - GuruFocus
ACRV: HC Wainwright Reiterates 'Buy' Rating and $19 Price Target - GuruFocus
HC Wainwright & Co. Reiterates Acrivon Therapeutics (ACRV) Buy Recommendation - Nasdaq
Optimistic Buy Rating for Acrivon Therapeutics, Inc. Driven by Promising ACR-368 Trial Developments - TipRanks
Will Acrivon Therapeutics Inc. stock see PE expansionWeekly Trade Recap & High Accuracy Trade Alerts - newser.com
Research Analysts Issue Forecasts for ACRV FY2025 Earnings - Defense World
Brokerages Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Target Price at $11.00 - Defense World
There is no way Acrivon Therapeutics Inc (ACRV) can keep these numbers up - Setenews
Acrivon Therapeutics stock rating reiterated by Citizens with $13 target - Investing.com Nigeria
Is Acrivon Therapeutics Inc. stock attractive for hedge fundsMarket Performance Recap & Capital Efficient Trade Techniques - newser.com
Will Acrivon Therapeutics Inc. stock split attract more investors2025 Momentum Check & Weekly Sector Rotation Insights - newser.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and Acrivon Therapeutics, Inc. (ACRV) - The Globe and Mail
Acrivon Therapeutics Narrows Losses And Draws Analyst Support - Finimize
Positive Outlook and Buy Rating for Acrivon Therapeutics, Inc. Based on Promising Clinical Data and Strategic Advancements - TipRanks
Acrivon Therapeutics Shrinks Losses And Draws Analyst Optimism - Finimize
Analysts’ Top Healthcare Picks: Acrivon Therapeutics, Inc. (ACRV), Sera Prognostics (SERA) - The Globe and Mail
Is Acrivon Therapeutics Inc. stock supported by strong cash flowsMarket Trend Report & Community Verified Watchlist Alerts - newser.com
Acrivon Therapeutics Reports Q3 2025 Financial Results - TipRanks
Acrivon Therapeutics Advances ACR-368 in Phase 2b Trial for Endometrial Cancer and Prepares for Initial Data on ACR-2316 - Quiver Quantitative
Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights - Bluefield Daily Telegraph
Does Acrivon Therapeutics Inc (ACRV) offer a good opportunity for investors? - Setenews
Why Acrivon Therapeutics Inc. stock is recommended by analystsWeekly Risk Summary & Free Daily Entry Point Trade Alerts - newser.com
Acrivon Therapeutics (ACRV) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Is Acrivon Therapeutics Inc. stock a contrarian buyQuarterly Market Summary & Free High Accuracy Swing Entry Alerts - newser.com
Will Acrivon Therapeutics Inc. stock benefit from green energy trendsWeekly Investment Report & Weekly Hot Stock Watchlists - newser.com
Acrivon Therapeutics (NASDAQ:ACRV) & Bioasis Technologies (OTCMKTS:BIOAF) Financial Analysis - Defense World
Custom strategy builders for tracking Acrivon Therapeutics Inc.Sell Signal & Precise Swing Trade Entry Alerts - newser.com
Acrivon Therapeutics reports preclinical data on ACR-2316 - BioWorld MedTech
Can Acrivon Therapeutics Inc. stock weather global recessionPortfolio Return Summary & Expert Approved Trade Ideas - newser.com
Acrivon Therapeutics Inc (ACRV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
1.57%
자본화:
|
볼륨(24시간):